Navigation Links
New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes
Date:6/28/2010

recommended blood pressure target was greater with the triple combination therapy (40/10/25 mg) versus corresponding dual combination therapy regardless of gender, age, race, and hypertension severity (P<0.0001).(7)

Safety & Tolerability

Across all groups, drug-related treatment adverse events (TEAEs) were reported in 25.4 percent of patients.(1)  Most TEAEs and drug-related TEAEs were mild or moderate in severity.(1) More discontinuations due to TEAEs occurred in the olmesartan medoxomil / amlodipine / hydrochlorothiazide (40/10/25 mg) (4.0 percent) versus the dual combination therapy groups (1.0 to 2.1 percent) and were due to adverse events such as dizziness and hypotension.(1) These discontinuations can potentially be attributed to the more pronounced pharmacodynamic effect of the triple combination therapy.(1) Peripheral edema also was a cause for discontinuation.(1)

In addition, discontinuations for patients on triple combination therapy also included subjects who experienced an adverse event on earlier treatment (i.e. placebo or dual), prior to initiation of the triple combination regimen.(1)

About The Triple Combination Therapy

A fixed-dose, single combination product of olmesartan medoxomil/ amlodipine / hydrochlorothiazide is currently under review for approval with the US Food and Drug Administration (FDA) for the treatment of hypertension.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engag
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 2 Data for Ultra-Long-Acting Insulin Degludec Shows the Potential to Effectively Lower Blood Sugar, Including When Used Three Times a Week
2. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
3. Highmark Study Shows Integrated Medical and Pharmacy Benefits Lower Costs, Promote Better Health
4. New Report Shows Record Number of Medicines Currently in Development to Treat Diabetes
5. Drug in New Class of Targeted Therapies Shows Early Promise Against Blood-Related Cancers
6. New Study Shows ENJUVIA® Significantly Reduced Sleep Time Awakenings Caused by Hot Flashes in Postmenopausal Women
7. Implanted Sleep Device Shows Promising Early Results
8. Data Shows Ambulance Fees Will Deter Emergency Calls for Help
9. New Study Shows 84 Percent Reduction in Post-Cesarean Section Infections Through Comprehensive Prevention Strategy
10. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
11. Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Reportlinker.com announces ... is available in its catalogue: ... Control (Sterilization, Disinfection, Testing and Treatment) ... Given the cost of ... has increased for solutions that can ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 /PRNewswire/ ... report is available in its catalogue: ... U.S. IVD Industry http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... Care Act" (H.R. 3590) is complex legislation that ... many of its provisions are beginning to take ...
(Date:8/20/2014)... YORK , Aug. 20, 2014 /PRNewswire/ ... research report is available in its catalogue: ... in France, Key Trends and Opportunities to ... Synopsis The report provides in ... the French personal accident and health insurance ...
Breaking Medicine Technology:The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23
... South Korea, Feb. 25 Dong-A PharmTech Co., ... Pharma, has initiated,a 200 patient, phase 2 proof ... udenafil, a long acting phosphodiesterase type 5 inhibitor, ... European,study is designed to investigate the safety and ...
... Enterprise Intelligence Systems to Healthcare Market, ... #1841 --,Harris Corporation (NYSE: HRS ), ... joined forces with Cancer Treatment,Services International (CTSI) ... oncology. Harris will provide advanced imaging and ...
Cached Medicine Technology:Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 2Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 3Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment 2
(Date:8/20/2014)... A common approach to treating kidney failure ... improve survival chances for people who suddenly developed the ... University of Pittsburgh School of Medicine. ... PLOS One , suggest acute hemodialysis, an aggressive ... kidney failure, may not provide a definitive benefit to ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Quincy Bioscience, ... Inc. 500|5000 list of the fastest growing private ... year. Ranking at No. 2,941, Quincy Bioscience is honored ... in the United States. , Quincy Bioscience is manufacturer ... apoaequorin – a protein originally discovered in jellyfish and ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The non-small ... increase considerably in the offing across the top 8 ... of 2013 to around USD 8 billion by 2020-end, ... The growth is projected to be driven by innovative ... is currently lacking efficient treatment, unlike the non-squamous segment. ...
(Date:8/20/2014)... By Steven Reinberg ... -- A rare birth disorder that dismantles a baby,s immune ... study of more than 3 million infants says. This ... for the life-threatening but treatable condition known as severe combined ... "People were made aware of this condition by the boy ...
(Date:8/20/2014)... -- New research reveals that, long ago, sea mammals ... of the infectious disease known as tuberculosis. Ancient ... seals and sea lions, who then spread it to ... to an international team of researchers. "Tuberculosis is ... This study and further research will help us understand ...
Breaking Medicine News(10 mins):Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2Health News:Quincy Bioscience Recognized in Inc. 500|5000 List of America’s Fastest Growing Companies for Third Consecutive Year 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 4Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3Health News:Seals, Sea Lions Helped Global Spread of TB, Study Finds 2
... , MASON, Ohio, Aug. 10 ... physicians representing the Women,s Dermatologic Society (WDS) will provide ... enjoying the Western & Southern Financial Group Master,s and Women,s ... a.m.-5:00 p.m. Led by board-certified dermatologist Allison Moosally, MD (Cleveland), ...
... PHILADELPHIA, August 10 , ... of System,s,Nine-Year "Journey to Excellence"; Elsevier Becomes Primary Information,Source ... http://www.elsevier.com ), a world leader in healthcare and,medical publishing ... of the top 10 Catholic health systems in the ...
... August 10 , - ... Help,Prevent Costly Mistakes; Hospitals Benefit From Averting the Reimbursement,Losses ... in healthcare and medical publishing and online,solutions, today announced ... Consult designed to help nurses prevent the 10 "Never ...
... ... US Drug Watchdog is intensifying its national efforts to get the word out ... Remedy Swabs. According to the group, "Our reasons are pretty simple. We fear ... has said, use of the products could result in a loss of taste, ...
... ... ... Tucson, Arizona is home to a dense Hispanic population. In recognition of September 15th ... word throughout the local Hispanic community that colorectal pre-screening can save lives., , , ...
... ... the publicly available iHOP database enables researchers to quickly and effectively use this invaluable ... ... of a new tutorial suite for iHOP, or Information Hyperlinked Over Proteins. iHOP ...
Cached Medicine News:Health News:Ohio Dermatologists to Help Tennis Community Get Into the Swing of Sun Safety 2Health News:CHRISTUS Health Selects Five Elsevier Clinical Decision Support Solutions to Transform Care Delivery for Patients, Physicians, Nurses and Pharmacists 2Health News:CHRISTUS Health Selects Five Elsevier Clinical Decision Support Solutions to Transform Care Delivery for Patients, Physicians, Nurses and Pharmacists 3Health News:CHRISTUS Health Selects Five Elsevier Clinical Decision Support Solutions to Transform Care Delivery for Patients, Physicians, Nurses and Pharmacists 4Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 2Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 3Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 4Health News:The US Drug Watchdog Calls Zicam Nasal Gel Or Zicam Swabs A National Disaster That May Have Caused People To Lose Their Sense Of Smell 2Health News:Hispanics at High Risk for Colorectal Cancer 2Health News:Hispanics at High Risk for Colorectal Cancer 3Health News:New Online Tutorial for iHOP from OpenHelix 2Health News:New Online Tutorial for iHOP from OpenHelix 3
... When the all silicone cuff ... no distinguishable dimension to the ... shaft, yet it can be ... varied airway management needs. TTS™ ...
... Adjustable Neck Flange Hyperflex™ Tracheostomy TubesSimilar ... tube features the more traditional and ... Aire-Cuf® Adjustable Neck Flange Hyperflex™ Tracheostomy ... wedge, and obturator/introducer device., ,NOTE: ...
... for easy ventilator circuit attachment with or ... tubes are available in five adult sizes, ... system allows quick identification and correct sizing ... ,The Portex® line of D.I.C.® tracheostomy tubes ...
Indications For Usage: ,For use with percutaneous tracheotomies...
Medicine Products: